As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.
12 Analysts have issued a Xeris Biopharma Holdings forecast:
12 Analysts have issued a Xeris Biopharma Holdings forecast:
Jun '25 |
+/-
%
|
||
Revenue | 246 246 |
36%
36%
|
|
Gross Profit | 202 202 |
33%
33%
|
|
EBITDA | 1.02 1.02 |
104%
104%
|
EBIT (Operating Income) EBIT | -9.82 -9.82 |
74%
74%
|
Net Profit | -32 -32 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.
Head office | United States |
CEO | John Shannon |
Employees | 394 |
Founded | 2005 |
Website | www.xerispharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.